Latest news with #SurgeryPartners
Yahoo
4 hours ago
- Business
- Yahoo
Surgery Partners, Inc. (SGRY): A Bull Case Theory
We came across a bullish thesis on Surgery Partners, Inc. on by Shoe. In this article, we will summarize the bulls' thesis on SGRY. Surgery Partners, Inc.'s share was trading at $22.47 as of July 14th. SGRY's trailing and forward P/E were 2.69k and 35.59 respectively according to Yahoo Finance. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Surgery Partners (SGRY), a major player in the ambulatory surgery center (ASC) space, presents a compelling special situation investment driven by a high-probability takeout by Bain Capital, which already owns 39% of the company. After a failed sale process in 2024 and a non-binding $25.75 per share offer from Bain in January 2025, the odds favor a full acquisition. Despite the stock fading from initial highs due to market volatility and macro fears, fundamentals remain intact: ASCs are a secularly advantaged model lower-cost, efficient care delivery and favorable patient outcomes. Surgery Partners, as the last pure-play public ASC, enjoys mid-teens EBITDA CAGR through a mix of organic growth and M&A, with solid strategic positioning in orthopedics and cardiology. Valuation upside is real; historical EV/EBITDA multiples for similar takeouts (UNH/SCAI, THC/USPI) support the view that Bain may need to bump its bid. Given prior trades above the bid and historical data showing bumps in ~95% of minority buyouts, a revised offer around $28 isn't far-fetched. The stock trades near technical support, and downside is cushioned at $18.5–$19.25. Jefferies and Nomura estimate Bain could still achieve >17% IRR with a takeout at $30, suggesting room for competitive interest or a strategic rerating. Recent Bain transactions worth $2B underscore its capacity to execute despite tightened credit markets. With a likely resolution in the coming weeks, possibly aligned with the unusual Monday earnings schedule, a successful deal could yield 12–23% upside. Meanwhile, Surgery Partners' ASC platform continues to benefit from favorable healthcare trends and operational improvements. Previously, we covered a on Tenet Healthcare Corporation (THC) by BlackSwanInvestor in December 2024, highlighting its debt reduction and growth in Ambulatory Care. The stock has appreciated by ~38% since, driven by execution in its ASC strategy. Shoe shares a similar thesis but emphasizes Surgery Partners' pure-play ASC positioning and potential near-term buyout by Bain Capital. Surgery Partners, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held SGRY at the end of the first quarter which was 24 in the previous quarter. While we acknowledge the potential of SGRY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
18-06-2025
- Business
- Business Insider
Mizuho Securities Reaffirms Their Buy Rating on Surgery Partners (SGRY)
In a report released today, Ann Hynes from Mizuho Securities reiterated a Buy rating on Surgery Partners (SGRY – Research Report), with a price target of $28.00. The company's shares closed today at $20.33. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Hynes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Acadia Healthcare, and Humana. According to TipRanks, Hynes has an average return of 8.9% and a 59.68% success rate on recommended stocks. Currently, the analyst consensus on Surgery Partners is a Moderate Buy with an average price target of $31.22, representing a 53.57% upside. In a report released today, Leerink Partners also reiterated a Buy rating on the stock with a $34.00 price target. The company has a one-year high of $33.97 and a one-year low of $19.50. Currently, Surgery Partners has an average volume of 998.6K.
Bloomberg
17-06-2025
- Business
- Bloomberg
Stock Movers: JetBlue, Solar Sector, Surgery Partners
On this edition of Stock Movers: - JetBlue (JBLU) plans to hasten cost cuts by eliminating some flights, ending service to a number of cities and restructuring its leadership ranks as economic uncertainty feeds weaker-than-expected demand for travel, the company said in an internal memo. The carrier will eliminate underperforming routes and plans to announce network changes in coming weeks, according to the memo from Chief Executive Officer Joanna Geraghty seen by Bloomberg on Tuesday. JetBlue implemented budget reductions at support centers and is assessing hiring, spending on business partners and vendors and will combine or restructure some leadership roles. The carrier has halted cosmetic refreshes of four out of its 10 legacy Airbus A320 aircraft used for flights and will park the planes at the end of summer. Shares initially rallied before paring gains. - Solar stocks, like Sunrun (RUN), SolarEdge (SEDG) and Enphase (ENPH) fell sharply after Senate Republicans released a bill that would end clean energy tax credits earlier than expected, dashing hopes that major cuts passed by the House wouldn't stick. The new version of the bill released by the Senate Finance Committee would end incentives for wind and solar in 2028. Tax breaks for other sources of power, such as nuclear, hydropower and geothermal, would be allowed to remain until being phased out in 2036, according to a summary of the legislation. - Surgery Partners (SGRY) shares tumbled as much as 14%, the most intraday since November 2024, after the company turned down a buyout proposal from Bain Capital, with its independent committee concluding that its long-term value as a standalone public company outweighs Bain's offer. The company also reaffirmed its revenue forecast for the full year.
Bloomberg
17-06-2025
- Business
- Bloomberg
Stock Movers: JetBlue, Lennar, Surgery Partners
On this episode of Stock Movers: - JetBlue (JBLU) shares are lower on plans to accelerate its cost reductions by eliminating some flights, pausing retrofits and parking some jets due to weaker-than-expected demand for travel. This is according to an internal memo, which CNBC reported on earlier. - Lennar (LEN) shares rise after a miss on the homebuilder's new orders outlook was tempered by better-than-expected gross margins, which RBC Capital Markets said should reassure investors. - Surgery Partners (SGRY) shares slide after the company turned down a buyout proposal from Bain Capital, with its independent committee concluding that its long-term value as a standalone public company outweighs Bain's offer.
Reuters
17-06-2025
- Business
- Reuters
Surgery Partners rejects Bain Capital's take-private offer
June 17 (Reuters) - Surgery Partners (SGRY.O), opens new tab said on Tuesday it was unable to agree to the terms set by Bain Capital, its largest shareholder, to take the surgical facility operator private. Surgery Partners' shares fell more than 13% to $20.10 in premarket trading. A special committee of independent directors has concluded that the best path forward for the company and its stockholders was to continue operating as an independent publicly traded company, Surgery Partners said. Bain Capital, which in January offered to acquire all the remaining shares of the company it does not already own for $25.75 apiece, has a 38.97% stake in Surgery Partners, according to LSEG data. The private equity firm did not immediately respond to Reuters' request for comment. Surgery Partners had previously attracted acquisition interest from private equity firm TPG (TPG.O), opens new tab and healthcare giant UnitedHealth Group (UNH.N), opens new tab, according to a Bloomberg News report in August 2024. The surgical facility operator plans to host an investor day in the second half of 2025 to present its strategy and outlook. The company also reiterated its annual revenue forecast of $3.3 billion to $3.45 billion, compared with analysts' average estimate of $3.38 billion.
